Ranbaxy CEO Says Purchase By Daiichi Not Threatened By Investigation
This article was originally published in PharmAsia News
The acquisition of Ranbaxy Laboratories by Daiichi Sankyo is still on track and cannot legally be derailed, according to the Indian firm's CEO. Malvinder Singh said his counterparts at Daiichi were aware the U.S. FDA had questions about some of Ranbaxy's generic drugs before the agency's investigation became public. Singh addressed a news conference in the wake of speculation the merger of the two giants might be scuttled by FDA's questions. He said there was no doubt the $4.6 billion deal was still alive. Daiichi confirmed the sale is final. (Click here for more - a subscription may be required
You may also be interested in...
Several experts spoke with Scrip about their take on how the biopharmaceutical industry's efforts to respond to COVID-19 might help industry's image problem.
Pharma pays $50m up front to tap insitro’s in vitro modeling technology, partners with Sensyne Health in blood disorders. Lilly’s COVID-19 partner AbCellera teams with Kodiak in ophthalmology R&D.
Early Research Suggests Wearables Can Spot Early Signs Of COVID-19; Fitbit Receives $2.5m Army Award
A consortium of researchers, including Fitbit, are developing algorithms to spot COVID-19 before people become ill.